Paper40189932
PD-L1 Scoring Models for Non-Small Cell Lung Cancer in China: Current Status, AI-Assisted Solutions and Future Perspectives.
Huang Z and 4 others. Thorac Cancer, 2025. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. PD-L1 Scoring Models for Non-Small Cell Lung Cancer in China: Current Status, AI-Assisted Solutions and Future Perspectives. Papers, record 40189932. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40189932
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- PD-L1 Scoring Models for Non-Small Cell Lung Cancer in China: Current Status, AI-Assisted Solutions and Future Perspectives.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| B7-H1 Antigen | Major topic |
| Artificial Intelligence | Major topic |
| Biomarkers, Tumor | Major topic |
| Humans | |
| China | |
| Prognosis | |
| Immunotherapy |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| MSD China | PubMed | |||
| 2021YFF1201001 | National Key Research and Development Program of China | PubMed | ||
| 23XHYD-12 | The Institution and Governmental Cooperative Project, Shanghai Xuhui District Science and Technology Committee | PubMed |
Source PubMed
References107
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33196892 | Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China. | J Cancer Res Clin Oncol | 2021 | https://conductscience.org/library/papers/33196892 | PubMed |
| 2 | 37383318 | Assessing the design of China's complex health system - Concerns on equity and efficiency. | Health Policy Open | 2020 | https://conductscience.org/library/papers/37383318 | PubMed |
| 3 | 36735893 | Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36735893 | PubMed |
| 4 | 29389679 | Artificial Intelligence in Surgery: Promises and Perils. | Ann Surg | 2018 | https://conductscience.org/library/papers/29389679 | PubMed |
| 5 | 37924090 | Continuing medical education in China: evidence from primary health workers' preferences for continuing traditional Chinese medicine education. | BMC Health Serv Res | 2023 | https://conductscience.org/library/papers/37924090 | PubMed |
| 6 | 32842436 | [Expert consensus on PD-L1 expression testing in non-small-cell lung cancer in China]. | Zhonghua Zhong Liu Za Zhi | 2020 | https://conductscience.org/library/papers/32842436 | PubMed |
| 7 | 32300181 | Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. | Mod Pathol | 2020 | https://conductscience.org/library/papers/32300181 | PubMed |
| 8 | 35840720 | Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab. | Mod Pathol | 2022 | https://conductscience.org/library/papers/35840720 | PubMed |
| 9 | 25565398 | A nationwide telepathology consultation and quality control program in China: implementation and result analysis. | Diagn Pathol | 2014 | https://conductscience.org/library/papers/25565398 | PubMed |
| 10 | 28885881 | Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28885881 | PubMed |
| 11 | 38983127 | Real‑world evidence of advanced non‑small cell lung carcinoma treated with an immune checkpoint inhibitor plus chemotherapy. | Oncol Lett | 2024 | https://conductscience.org/library/papers/38983127 | PubMed |
| 12 | 34689789 | PD-L1 immunostaining: what pathologists need to know. | Diagn Pathol | 2021 | https://conductscience.org/library/papers/34689789 | PubMed |
| 13 | 35174655 | The ethical challenges of artificial intelligence-driven digital pathology. | J Pathol Clin Res | 2022 | https://conductscience.org/library/papers/35174655 | PubMed |
| 14 | 32007657 | Cytology for PD-L1 testing: A systematic review. | Lung Cancer | 2020 | https://conductscience.org/library/papers/32007657 | PubMed |
| 15 | 34565707 | PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort. | Clin Lung Cancer | 2022 | https://conductscience.org/library/papers/34565707 | PubMed |
| 16 | 39257157 | Regulating algorithmic care in the European Union: evolving doctor-patient models through the Artificial Intelligence Act (AI-Act) and the liability directives. | Med Law Rev | 2025 | https://conductscience.org/library/papers/39257157 | PubMed |
| 17 | 33979398 | A fast and effective detection framework for whole-slide histopathology image analysis. | PLoS One | 2021 | https://conductscience.org/library/papers/33979398 | PubMed |
| 18 | 31656061 | Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists. | J Pathol Transl Med | 2019 | https://conductscience.org/library/papers/31656061 | PubMed |
| 19 | 37078210 | [Expert consensus on PD-L1 expression testing in esophageal carcinoma in China]. | Zhonghua Zhong Liu Za Zhi | 2023 | https://conductscience.org/library/papers/37078210 | PubMed |
| 20 | 27913228 | PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. | J Thorac Oncol | 2017 | https://conductscience.org/library/papers/27913228 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41357215 | Beyond monotherapy: multimodal strategies integrating immune checkpoint inhibitors in lymphoma management. | Front Immunol | 2025 | https://conductscience.org/library/papers/41357215 | PubMed |
| 40968169 | Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC. | NPJ Precis Oncol | 2025 | https://conductscience.org/library/papers/40968169 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40189932
GET https://conductscience.org/api/papers/v1/40189932/references?page=2